Jiwan Qiu

This inventor holds 6 USPTO granted patents and 5 published patent applications and 5 EPO patents. Top assignees: Qyuns Therapeutics Co., Ltd., Qyuns Therapeutics Co., Ltd., Jiangsu Qyuns Therapeutics Co., Ltd.. Active years: 2024-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jiwan Qiu. Retrieved from https://idiyas.com/inventor/jiwan-qiu-l0hv2wok

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 6 (Patent Applications = 5)

% Patents Active = 100.0

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 6.6

ph-index = 1

Company Filing History:

3 out of 4

Qyuns Therapeutics Co., Ltd.

patents

2 out of 2

Qyuns Therapeutics Co., Ltd.

patents

1 out of 1

Jiangsu Qyuns Therapeutics Co., Ltd.

patent

Years Active: 2024-2026

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12692303 - ANTI-HUMAN INTERLEUKIN 23 MONOCLONAL ANTIBODY AND APPLICATION THEREOF (2026-07-28),

2. 12552870 - ANTI-HUMAN INTERLEUKIN 36 RECEPTOR MONOCLONAL ANTIBODY AND METHODS OF USE THEREOF TO TREAT DISEASE (2026-02-17),

3. 12378309 - Anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody and use thereof to treat disease (2025-08-05),

4. 12351626 - Anti-human interleukin-33 monoclonal antibody and use thereof (2025-07-08),

5. 12297280 - Monoclonal antibodies against human interleukin-4 receptor alpha, encoding nucleic acids thereof and method of use thereof to treat IL-4 or IL-4/IL-13-mediated diseases (2025-05-13),

6. 12110323 - Anti-human interleukin 17A monoclonal antibody and application thereof (2024-10-08),

Title: Jiwan Qiu: Innovator in Monoclonal Antibody Development

Introduction

Jiwan Qiu is a prominent inventor based in Jiangsu, China, known for his significant contributions to the field of monoclonal antibodies. With a total of four patents to his name, he has made strides in developing therapeutic solutions for various diseases.

Latest Patents

Among his latest patents is the invention of an anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody. This antibody exhibits high affinity for human TSLP and possesses neutralizing activity, making it a potential treatment for TSLP-mediated diseases. Another notable patent is the anti-human interleukin-33 monoclonal antibody, which also demonstrates high affinity and neutralizing activity, aimed at preventing or treating diseases related to human interleukin-33.

Career Highlights

Jiwan Qiu has worked with several companies, including Qyuns Therapeutics Co., Ltd. and Jiangsu Qyuns Therapeutics Co., Ltd. His work in these organizations has been pivotal in advancing research and development in therapeutic antibodies.

Collaborations

Throughout his career, Jiwan has collaborated with notable colleagues such as Wei Chen and Yiliang Wu, contributing to a dynamic research environment that fosters innovation.

Conclusion

Jiwan Qiu's work in monoclonal antibody development showcases his dedication to advancing medical science. His innovative patents and collaborations highlight his role as a key figure in the field.

Profile summary based on public USPTO records.